Apps for Automated Atrial Fibrillation and Prolonged QT Interval Detection will be Included in the Scope of
Detection Options
Toronto, Ontario--(Newsfile Corp. - March 5, 2019) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the
"Company"), a global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management
software solutions, is preparing US Food and Drug Administration ("FDA") 510(k) Class II medical device clearance
applications for new arrhythmia detection algorithms.
The main application will be for GEMS™ Rhythm, a full suite of arrhythmia detection tools designed for use with GEMS™ WIN, which
is licensed to hospitals, clinics and commercial ECG scanning services. GEMS™ Rhythm will support long-term, continuous recordings
of ECGs that are associated with new and higher paying reimbursement codes in Canada and the US. GEMS™ Rhythm will also be capable
of running on smartphones, removing the dependence on access to cloud-based systems for the collection and interpretation of ECG
data.
The Company will also seek approvals for GEMS™ Rhythm AF and GEMS™ Rhythm QT for consumer and prescription use. These
auto-detection algorithms will be available as add-on features to the recently FDA- cleared GEMS™ Mobile app, the only iOS and
Android smartphone ECG app that can connect to different manufacturers' ECG monitoring devices. GEMSTM Mobile with
Rhythm AF will compete against solutions from AliveCor, Apple and others.
GEMS™ Rhythm QT would be the first QT interval prolongation screening solution released for smartphone use. QT interval
abnormalities have been associated with sudden cardiac death sometimes seen in athletes and in patients prescribed certain
medications. These abnormalities are better detected by devices like CardioComm's HeartCheck™ ECG PEN and HeartCheck™ CardiBeat,
both of which allow a lead II ECG trace to be recorded.
The ability for GEMS™ Mobile to link consumer use of ECG devices to hospitals where GEMS™ WIN is licensed extends the patient
monitoring experience beyond the fixed and short-term use of traditional, large and expensive ECG monitoring devices. This should
lead to better patient care outcomes and open additional billing code revenue-generating opportunities for health care
organizations.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please see the
Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an
external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification,
is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial
condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm
Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on
information currently available to management. By their nature, forward-looking statements and forward-looking information involve
risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many
factors that could cause actual results and developments to differ materially from those expressed or implied by these
forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking
information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information
contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
![Corporate Logo](https://orders.newsfilecorp.com/files/1775/43240_f38ecfd1148839d7_logo.jpg)
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43240